aibio
Distress ·
Acrivon ends Akoya companion diagnostic agreement and takes testing in-house
The February 25, 2026 termination involves no payments. Acrivon keeps full rights to its ACR-368 OncoSignature test.
ACRV Acrivon Therapeutics, Inc.
Acrivon Therapeutics (ACRV) news
Latest Acrivon Therapeutics news
We have not published a story on Acrivon Therapeutics yet. When there is news, it will appear here.
Acrivon Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $60.0 million | $64.0 million |
| Net income (loss) | -$77.9 million | -$80.6 million |
| Cash from operations | -$63.7 million | -$65.7 million |
| Cash and equivalents | $41.5 million | $39.8 million |
| Short-term investments | $77.1 million | $139.7 million |
Questions about Acrivon Therapeutics
What is the ticker symbol of Acrivon Therapeutics?
Acrivon Therapeutics, Inc. trades under the ticker ACRV on NASDAQ.
Where is Acrivon Therapeutics listed?
Acrivon Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Acrivon Therapeutics?
The SEC Central Index Key (CIK) for Acrivon Therapeutics, Inc. is 1781174. Its filings are on SEC EDGAR.
How many shares does Acrivon Therapeutics have outstanding?
42,853,362 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-12.
Which country or territory is Acrivon Therapeutics listed under?
Our directory records Acrivon Therapeutics, Inc. under United States.
What does Acrivon Therapeutics do?
Our directory classifies Acrivon Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Acrivon Therapeutics?
The ISIN recorded for Acrivon Therapeutics, Inc. is US0048901096.
Does aibio.space cover Acrivon Therapeutics?
aibio.space lists Acrivon Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Is Acrivon Therapeutics profitable?
Acrivon Therapeutics, Inc. reported a net loss of $77.9 million for the fiscal year ended Dec 31, 2025, and used $63.7 million of cash in operations, per its annual report to the SEC.
How much does Acrivon Therapeutics spend on research and development?
$60.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Acrivon Therapeutics have?
$90.0 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Acrivon Therapeutics (ACRV) stock news?
Our latest story on Acrivon Therapeutics, dated Mar 2, 2026: "Acrivon ends Akoya companion diagnostic agreement and takes testing in-house". The February 25, 2026 termination involves no payments. Acrivon keeps full rights to its ACR-368 OncoSignature test. Source.
Is Acrivon Therapeutics in financial distress?
Our latest distress story, dated Mar 2, 2026: "Acrivon ends Akoya companion diagnostic agreement and takes testing in-house". The February 25, 2026 termination involves no payments. Acrivon keeps full rights to its ACR-368 OncoSignature test. Source.
What is Acrivon Therapeutics's market cap?
We do not publish live share prices. In its annual report, Acrivon Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $20.4 million as of Jun 30, 2025.
Is Acrivon Therapeutics a smaller reporting company?
SEC records list Acrivon Therapeutics, Inc.'s filer category as: <br>Emerging growth company.
Investor discussion: Acrivon Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Distress
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Stock chart
SEC filings and registration
- SEC name
- Acrivon Therapeutics, Inc.
- CIK
- 1781174
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- ACRV (Nasdaq)
- Fiscal year ends
- December 31
- Filer category
- <br>Emerging growth company
- Business address
- 480 ARSENAL WAY, SUITE 100, WATERTOWN, MA, 02472
- Phone
- 617-207-8979
- Shares outstanding
- 42,853,362 as of 2026-08-07 (10-Q filed 2026-08-12)
Recent filings
Listing details
- Company
- Acrivon Therapeutics, Inc.
- Ticker
- ACRV
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US0048901096
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction